Optimizing conventional neonatal ventilation

46% of ventilated neonatal patients experience neonatal respiratory distress syndrome (nRDS)

Only 9% of ventilated neonates are treated with Volume Guarantee (VG)

Robust technology for vulnerable infants

The AVEA® VG is designed to use the lowest possible pressure to maintain the desired exhaled tidal volume (Vte).

Why VG is important in nRDS

VG with pressure support ventilation (PSV) results in decreased levels of the inflammatory mediators interleukin-6 (IL-6) and interleukin-8 (IL-8) in neonates with nRDS.

Volume targeted strategies, such as VG, have been shown to reduce chronic lung disease and death.

CareFusion® helps you care for neonates through:
- Webinars
- Training materials
- CareFusion Learning Portal

carefusion.com/AVEA-Neonatal-VG

References